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http://dx.doi.org/10.1016/j.jmii.2013Bacillus cereus is an aerobic Gram-positive, spore-forming, rod-shaped bacterium that is
responsible for foodborne illnesses. We report on a 15-year-old girl with B-cell acute lympho-
blastic leukemia, who fell into a somnolent state after presenting with a 12-hour history of fe-
ver, muscle soreness, myalgia in both calves, sore throat, and vomiting. Fulminant septicemic
syndrome caused by B. cereus was finally identified. The aim of this work is the introduction of
B. cereus as a differential diagnosis of sepsis in patients with acute leukemia in induction
chemotherapy, to prevent delayed treatment.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Bacillus cereus, an aerobic Gram-positive, rod-shaped,
spore-forming bacterium, is widely distributed in thent of Pediatrics, Tri-Service
edical Center, Number 325,
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an Society of Microbiology. Publis
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.06.010environment and is usually considered a contaminant when
recovered from cultures. Although it commonly causes
foodborne gastroenteritis, which is mostly benign and self-
limiting, it occasionally causes severe infections in immu-
nocompromized patients, including septic shock, menin-
gitis, brain abscess, colitis, endocarditis, respiratory
infections, and infection-related coagulopathy and hemo-
lysis. Inoue et al reviewed 58 case reports of B. cereus
sepsis in patients with leukemia and found that only 28
of those patients survived.1 We present a fatal case of
B. cereus sepsis in a patient with acute leukemia.hed by Elsevier Taiwan LLC. This is an open access article under the
4.0/).
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A 15-year-old girl presented to hospital with a 7-day history
of fever, sore throat, abdominal fullness, yellowish skin
color, and general weakness. Based on her physical symp-
toms, clinicians at the hospital diagnosed tonsillitis and the
patient received medicine. Her symptoms, however, did
not subside, and the patient was taken to a different hos-
pital. Liver function tests performed at that time revealed
elevated levels of aspartate aminotransferase (1356 units/
L), alanine aminotransferase (1930 units/L), and anemia
(hemoglobin Z 8.1 g/dL). She was referred to our hospital
3 days later, where an initial diagnosis of acute hepatitis
was made.
After admission, complete blood count showed a he-
moglobin level of 6.5 g/dL and a platelet count of 19,000/
mm3. The white blood cell (WBC) count was 17,570/mm3,
with 5% segmented neutrophils, 43% lymphocytes, 9%
atypical lymphocytes, and 43% immature cells. After a se-
ries of examinations, acute B-cell lymphoblastic leukemia
was diagnosed. Based on the TPOG-2002-ALL protocol, the
patient was classified as belonging to the very high risk
group. The Taiwan Pediatric Oncology Group (TPOG) was
formed with the cooperation of all leukemia treatment
centers in Taiwan in 1988 and has since initiated national
cooperative group studies. A TPOG-2002-ALL VHR induction
phase protocol was started 3 days after admission. Pred-
nisolone 40 mg/m2 was administered. Within 2 days, there
was a marked decrease in blast cell count and WBC count,
indicating a good response. However, neutropenic fever
was noted. In response, cefepime (1 g by intravenous drip,
twice daily) was administered as empiric therapy. Urine
culture grew Escherichia coli (>105 colonies/mL), which
was susceptible to ampicillin, gentamicin, and cefepime.
Four days after induction chemotherapy, the patient
experienced a sleepless and restless night, and had a fever
of 38e39 C. Skin rashes over the forehead, a sore throat,
and myalgia over both lower limbs, in addition to another
fever spike (40.1 C) and one vomiting incident, were noted
the next morning.
Sudden onset of consciousness disturbance, with ani-
socoric pupils occurred 2 hours later. The Glasgow Coma
Scale was 8. Endotracheal intubation was performed. Brain
computed tomography showed no intracranial hemorrhage.
During the next 2 days, the patient suffered from four
episodes of pulseless electrical activity, with a return of
spontaneous circulation after resuscitation. Inotropic
agents, including dopamine, epinephrine, dobutamine,
norepinephrine, empiric antibiotics comprising meropenem
(1 g by intravenous drip, 3 times daily), vancomycin (1 g by
intravenous drip, 3 times daily), acyclovir (500 mg by
intravenous drip, 3 times daily), fluconazole (400 mg by
intravenous drip, once daily), and granulocyte colony-
stimulating factor, were administered. However, the pa-
tient’s general condition worsened. There was a rapid onset
of epistaxis, gastrointestinal (GI) bleeding, menorrhagia,
hematuria, and hypoalbuminemia, in addition to acute
renal failure and acute pulmonary edema. The patient died
2 days after onset of the symptoms of septic shock.
Rectal, throat, and urine samples were analyzed to
determine the causative agent. The results of all testsperformed (urine culture, blood culture, PCR for entero-
virus, influenza, and adenovirus) revealed Gram-positive
bacilli in three sets of blood cultures. The isolates were
subjected to 16S ribosomal RNA gene sequencing using the
broad-range bacterial specific primer pair Bact 5F (GAA
GAG TTT GAT CMT GGC TC) and Bact 809R (GCG TGG ACT
ACC AGG GTA TC), which is highly conserved throughout the
phylogenetic tree and is found in all prokaryotic organ-
isms.2,3 The product was compared with known sequences
in the National Center for Biotechnology Information (NCBI)
blast database and the result confirmed the presence of
B. cereus. Therefore, B. cereus-induced fulminant septi-
cemic syndrome was diagnosed.Discussion
The incidence of B. cereus septicemia accounts for
approximately 2% of all cases of bacteremia or fungemia.4
There have been several reports of B. cereus septicemia in
patients receiving cancer chemotherapy, especially in pa-
tients with hematologic malignancies.5e15 All had severe
neutropenia and high fever. The clinical course was fulmi-
nant, and death was rapid. In our patient, who had acute
lymphoblastic leukemia, and who was severely neutropenic
and iatrogenically immunosuppressed due to chemotherapy,
fatal septicemic shock, and coma caused by B. cereus
developed rapidly. The clinical course in our patient was
compatible with that reported by Musa et al, which was
marked by two phases: a mild febrile illness lasting 6e14
hours, accompanied by subtle symptoms of autonomic
sympathetic nervous system overactivity, and a second short
fulminant phase, marked by high fever (40e41 C) accom-
panied by major central nervous system (CNS) disturbances,
resulting in deep coma and brain stem dysfunction.16
Inoue et al reported on 12 cases and analyzed a total of
58 previously reported cases of B. cereus septicemia in
patients with hematologic malignancies.1 They found that
acute leukemia, a neutrophil count of near 0/mL, or the
presence of CNS symptoms during febrile episodes, were
associated with a fatal prognosis. Their findings are
compatible with the clinical presentation of our patient.
In our patient, all three sets of blood cultures showed
Gram-positive bacilli, and the laboratory staff considered it
as a contaminant. However, the three sets of blood cultures
were sampled from different sites and at different times
using sterile procedures. Therefore, it is unlikely that the
samples were contaminated. B. cereus was definitively
diagnosed after a full PCR workup. According to a previous
study, the presence of B. cereus in blood cultures should
not be regarded as contamination in patients receiving
intensive chemotherapy for leukemia.1,4,17
Our patient was treated with meropenem and vanco-
mycin after she manifested symptoms of septic shock. Ac-
cording to a previous study, all of the isolated B. cereus
strains were sensitive to imipenem, vancomycin, levo-
floxacin, and gentamicin, and the authors strongly recom-
mend immediate initiation of treatment with meropenem
and vancomycin in such situations. However, they also
experienced cases of fatal B. cereus sepsis, in which
appropriate antibiotic treatments were not effective.1
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been diagnosed in a limited number of pediatric patients
undergoing chemotherapy for hematological malig-
nancy.1,7,14,16,18e22 Based on the information available on
the 15 previously reported cases as well as our case, we
evaluated the risk factors for mortality among patients with
sepsis due to that bacterial species. The results are pre-
sented in Table 1. The variables that we analyzed included
age, sex, underlying diseases, chemotherapy treatment
process, presence of GI symptoms, CNS lesions, use of
corticosteroids, vancomycin, and absolute neutrophil count
(ANC). The 16 pediatric patients (8 boys, 8 girls) ranged in
age from 3 years to 17 years. Of the 16 patients, 11 had
acute lymphoblastic leukemia, two had acute myeloid
leukemia, one had acute leukemia, one had myelodys-
plastic syndrome, and one had non-Hodgkin lymphoma. GITable 1 Comparison of mortality rate of children with
Bacillus cereus sepsis
Characteristic Death Recovery p*
(n Z 6) (n Z 10)
Age
<10 y 1/6 (16.7) 4/10 (40) 0.59
>10 y 5/6 (83.3) 6/10 (60)
Sex
Male 3/6 (50) 5/10 (50) 0.99
Female 3/6 (50) 5/10 (50)
Disease
ALL 4/6 (66.7) 7/10 (70) 0.99
AML 1/6 (33.3) 1/10 (10)
Chemotherapy treatment process
Induction 4/6 (66.7) 3/10 (30) 0.12
Non-induction 0/6 (0) 5/10 (50)
Reinduction 2/6 (33.3) 2/10 (20)
GI symptom
Positive 4/6 (66.7) 6/10 (60) 0.99
Negative 2/6 (33.3) 4/10 (40)
CNS lesion
Positive 4/6 (66.7) 4/10 (40) 0.61
Negative 2/6 (33.3) 6/10 (60)
Corticosteroida
Use 3/4 (75) 6/6 (100) 0.40
Non-use 1/4 (25) 0/6 (0)
VCMb
Use 2/5 (40) 2/5 (40) 0.99
Non-use 3/5 (60) 3/5 (60)
WBC (ANC) (cells/mm3)c
ANC < 100 5/5 (100) 3/3 (100) 0.99
a In the corticosteroid use analysis, no data were available for
six patients.
b In the VCM use analysis, no data were available for six
patients.
c In the WBC (ANC) count analysis, no data were available for
eight patients.
Data are number (%) of patients.
*Based on Fisher’s exact test.
ALL Z acute lymphoblastic leukemia; AML Z acute myeloid
leukemia; ANC Z absolute neutrophil count; VCM Z
vancomycin; WBC Z white blood cell.symptoms were present in 10 patients and nine patients
had CNS lesions. In analysis of both the use of corticoste-
roids and vancomycin, no data were available for six pa-
tients. Of the 10 patients with available data, nine received
corticosteroids and four received vancomycin. In the WBC
count analysis, no data were available for eight patients.
All of the eight patients with available WBC count had se-
vere neutropenia (ANC < 100 cells/mL) and five of them had
an ANC of 0. In addition, six of the 16 patients died. Some
differences in age, chemotherapy treatment process,
presence of CNS lesions, and use of corticosteroids were
noted between patients who survived and those who died.
However, there were no significant differences in abnor-
malities between the two groups. In addition, there was no
significant difference in the use of vancomycin between the
two groups. Interestingly, however, all isolates of B. cereus
were susceptible to vancomycin and imipenem/meropenem
and resistant to penicillins and cephalosporins. In addition,
most isolates were susceptible to amikacin, gentamicin,
chloramphenicol, and erythromycin.1,16,18,19,22
The descriptions of the patient in this article should
alert clinicians to the potentially serious nature of B. cereus
infection in immunocompromized patients. Appropriate
antibiotics should be given as soon as B. cereus is detected
in any blood culture sample obtained from a patient with
hematological disease, especially in patients receiving
intensive chemotherapy.
In conclusion, B. cereus isolated from blood from
immunocompromized hosts should not be indiscriminately
regarded as a contaminant. Appropriate antibiotics should
be given as soon as B. cereus is detected in any blood cul-
ture sample obtained from patients undergoing intensive
chemotherapy for hematological disease. Based on our
findings, B. cereus should be included in the differential
diagnosis of sepsis in patients with acute leukemia who are
undergoing induction chemotherapy.References
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